Combo Improves Outcomes in Waldenstrom ' s Macroglobulinema Combo Improves Outcomes in Waldenstrom ' s Macroglobulinema

The combination of ibrutinib plus rituximab dramatically extends progression-free survival over rituximab alone, regardless of treatment or mutational status.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news